The Renin-Angiotensin System: Angiotensin II, Blood Pressure, and a Peptide Blocked and Given

The renin-angiotensin system (RAS), often written RAAS to include aldosterone, is one of the body's master controllers of blood pressure and fluid balance. At its heart is a single, extraordinarily powerful peptide — angiotensin II — and the story of how medicine both blocks and administers that same peptide is one of the most instructive in pharmacology.

The cascade

The system is a relay that springs into action when blood pressure or blood volume falls:

1. Renin. Specialized kidney cells sense low pressure or low sodium and release the enzyme renin into the blood.
2. Angiotensin I. Renin cleaves a liver protein, angiotensinogen, into angiotensin I — biologically fairly inert.
3. Angiotensin II. Angiotensin-converting enzyme (ACE), found mainly in the lungs, converts angiotensin I into angiotensin II, the active effector — an eight-amino-acid peptide.

Angiotensin II then does several things that all raise blood pressure: it powerfully constricts blood vessels (via AT1 receptors), stimulates the adrenal glands to release aldosterone (which retains salt and water), and promotes thirst and vasopressin release. It is the body's most potent natural vasoconstrictor.

Blocking the system: ACE inhibitors and ARBs

Because an overactive RAS contributes to hypertension, heart failure, and kidney disease, two of the most widely used drug classes in medicine are designed to shut it down:

• ACE inhibitors (ramipril, lisinopril, etc.) block the enzyme that makes angiotensin II, so less of it is formed.
• ARBs (angiotensin-receptor blockers such as losartan) block the AT1 receptor, so angiotensin II can't act.

Both lower blood pressure and protect the heart and kidneys over the long term. This is the RAS most people encounter — a system to be turned down.

Giving the system: angiotensin II as a vasopressor

Here is the twist. In distributive (vasodilatory) shock — most often septic shock — the blood vessels dilate pathologically and blood pressure collapses. Some patients stay dangerously hypotensive even on high doses of standard vasopressors like norepinephrine and vasopressin. For these patients, doctors do the opposite of chronic RAS blockade: they give angiotensin II itself as a drug.

Synthetic angiotensin II (brand name Giapreza), FDA-approved in 2017, is infused to constrict vessels through the AT1 pathway — a mechanism completely distinct from catecholamines and vasopressin. In its pivotal ATHOS-3 trial, adding angiotensin II improved the blood-pressure response in catecholamine-resistant vasodilatory shock. Because it is such a strong vasoconstrictor, it carries a risk of blood clots, so clot prophylaxis is recommended during use.

The same molecule, two directions

| Setting | Goal | What we do to angiotensin II |

| --- | --- | --- |

| Chronic hypertension, heart failure, kidney disease | Lower blood pressure | Block it (ACE inhibitors, ARBs) |

| Acute distributive shock | Raise blood pressure | Give it (Giapreza) |

That a single peptide can be the villain to block in one disease and the rescue to administer in another captures something deep about physiology: the RAS is not "good" or "bad," it is a control system, and medicine works by nudging it in whichever direction the situation demands.

A protective counter-arm

The RAS also has a lesser-known protective branch, in which a different enzyme (ACE2) produces angiotensin-(1-7), a peptide that tends to oppose angiotensin II's effects — vasodilating and anti-inflammatory. This counter-regulatory arm is an active area of research and a reminder that the system is a finely balanced network, not a one-way street.

> This article is educational and not medical advice. RAS-active drugs, including angiotensin II, are prescription medicines; the vasopressor form is used only in intensive care.